Αρχειοθήκη ιστολογίου

Κυριακή 24 Απριλίου 2016

Minithyrotomy with radiofrequency-induced thermotherapy (RFITT) for the treatment of adductor spasmodic dysphonia.

Minithyrotomy with radiofrequency-induced thermotherapy (RFITT) for the treatment of adductor spasmodic dysphonia.

Laryngoscope. 2016 Apr 23;

Authors: Desai SC, Park AM, Chernock RD, Paniello RC

Abstract
OBJECTIVES/HYPOTHESIS: A simple, safe and effective surgical alternative for treating adductor spasmodic dysphonia (ADSD) would appeal to many patients. This study evaluates a new option, using radiofrequency-induced thermotherapy (RFITT) of the thyroarytenoid muscle (TA) via the minithyrotomy approach to reduce the force of adduction.
METHODS: Fifteen dogs were used. In part 1, the optimal RFITT power settings, exposure time, probe location, and number of passes were determined. Part 2 compared laryngeal adductor pressures (LAPs) at baseline; immediately postintervention; and at 1, 3, or 6 months postintervention. Interventions included RFITT via the transcervical minithyrotomy approach (n = 15), transoral RFITT (n = 3), botulinum toxin (Botox) injection (n = 3), or no-intervention controls (n = 3). Postintervention induced phonation and histologic analyses were performed as well.
RESULTS: In the minithyrotomy RFITT group, the mean LAP was 30.3% of baseline immediately posttreatment. At 1, 3, and 6 months postoperatively, the mean LAPs were 24.9%, 44.8%, and 43.5%, respectively. Transoral RFITT reduced LAP to 56.6% of baseline immediately posttreatment, but returned to normal in the 1 and 3 month animals. The Botox injections dropped the LAP to 57% of baseline at 1 month, but returned to normal at 3 months. Mucosal waves, based on induced phonation stroboscopy, were present at the terminal date in all animals. Thirteen of 15 transcervical RFITT preparations (87%) showed no injury to the lamina propria, whereas 80% showed evidence of TA muscle atrophy and fibrosis.
CONCLUSION: Minithyrotomy RFITT is a feasible technique that shows encouraging long-term results for the potential treatment of patients with ADSD.
LEVEL OF EVIDENCE: N/A. Laryngoscope, 2016.

PMID: 27107402 [PubMed - as supplied by publisher]



from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1Tr3czS
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου